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Table 1
Racial distribution of study population
Chinese Malay Indian Others
Frequency 314 53 7 17
Percentage (80.3%) (13.6%) (1.8%) (4.3%)
Table 2
Summary of primary and secondary outcomes
No of conventional
induction
chemotherapy
Patients who achieved CR
One cycle
(n¼245)
Two cycles
(n¼61)
> 2 cycles
(Primary Resistant
AML) (n¼7)
CR rate (%) 65.7 15.6 1.8
Duration of CR (days)
Median 273 209 206
Range (183 e 468) (114 e 562) (173 e 301)
Relapse rate (%) 42.4 40.9 85.7
Undergone
hematopoietic
stem cell
transplantation (%)
56.3 60.7 85.7
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The prognosis for patients (pts) with r/r ALL is poor especially
after transplantation. Blinatumomab, an investigational
bispeciﬁc T-cell engager (BiTE) antibody construct that re-
directs T cells to CD19+ B cells resulting in serial lysis, has
shown antileukemia activity in pts with r/r ALL. We evalu-
ated the transplantation rate after blinatumomab-induced
remission, in pediatric patients with r/r ALL characterized by
negative prognostic factors, such as refractory disease and
prior alloHSCT.
In this single-arm study, eligible pts were 218 yrs old and
had an M3 marrow with B-precursor ALL that was refractory,
in 2nd marrow relapse, or any marrow relapse after HSCT;
and no CNS leukemia. A stepwise dose (wk 1: 5 mg/m2/d;
thereafter: 15 mg/m2/d) of blinatumomab was given by
continuous IV infusion (4 wks on/2wks off) for up to 5 cycles.
Primary endpoint was complete remission (CR) rate within 2
cycles. Secondary endpoints were alloHSCT rate, relapse-free
survival (RFS), overall survival (OS), and adverse events (AEs).
39 pts received blinatumomab. Median (range) age was 9
(2e16) yrs. 69% of pts had50% bonemarrow blasts. 41% had
1 prior salvage, 41% had 2 prior salvages and 18% were
primary refractory or had refractory relapse. 87% of pts
enrolled had relapsed within 6 months after the last remis-
sion. Among pts with prior alloHSCT (64%), 16% had 1 relapse
and 50% had 2 relapses. Of 12 pts (31%; 95% CI, 17%e48%)
who reached CR within the ﬁrst 2 cycles, 6 (50%) proceeded
to alloHSCT. 5 pts who did not respond to blinatumomab
received alloHSCT after treatment was ended. Donors
included haploidentical parents (n¼9), a sibling (n¼1) and an
unrelated donor (n¼1). AlloHSCT were performed at 8
different centers. Conditioning regimens included 5 mye-
loablative, 5 reduced intensity, and 1 unknown regimen.
Median (95% CI) RFS was 5.6 (2.6e12.1) months among bli-
natumomab responders and 6.5 (2.2e7.7) months among
responders receiving alloHSCT (measured from the time of
alloHSCT). At 6-month follow-up, median (95% CI) OSwas 4.3
(3.6e8.1) months among all pts and 7.7 (0.45eNE) months
among pts receiving alloHSCT (measured from the time of
alloHSCT).100-daymortality rate post alloHSCTwas 10%. The
most common AEs among all pts included pyrexia (74%),
anemia (33%), nausea (31%), headache (28%) and hyperten-
sion (26%). Anemia (26%), pyrexia (21%), increased alanine
aminotransferase or aspartate aminotransferase (18% each)
and febrile neutropenia (15%) were the most common grade
3 AEs. 3 (8%) pts (2 with grade 3 events) had cytokine-
release syndrome.
In this phase I/II study, blinatumomab has shown promising
antileukemia activity in pediatric patientswith r/r B-precursor
ALL, most of whom had prior alloHSCT and/or were refractory.
Half of pts who achieved CR in response to blinatumomabproceeded to alloHSCT, suggesting that blinatumomab may
provide a therapeutic option to bridge this patient population
to alloHSCT.243
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Background: Though there has been signiﬁcant improve-
ment in the outcome of adult patients with acute myeloid
leukemia (AML), much of this has been attributed to advance
in supportive care. Response to therapy has been a key pre-
dictor of clinical outcome in patients with newly diagnosed
AML. Published studies have identiﬁed prognostic factors in
predicting treatment response for AML induction therapy
but data is lacking in Asian population.
Objectives: To evaluate the response rates of conventional
induction chemotherapy in patients with AML in a tertiary
care hospital and to identify prognostic factors associated
with primary resistant AML.
Methods: This retrospective study included newly diag-
nosed AML patients who received conventional induction
chemotherapy at Singapore General Hospital between
January 1999 and June 2013. Primary outcome of the study
was to determine the response rates to treatment. Secondary
outcomes included duration of CR, relapse rate, overall sur-
vival (OS), and pre-treatment prognostic factors associated
with primary resistant AML. Primary resistant AML was
deﬁned as failure to achieve CR within two cycles of induc-
tion chemotherapy.
Figure 1. Kaplan-Meier analysis of OS
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(range 13 e 79), were included. The most common induction
chemotherapy used was IA 3+7 (idarubicin 12mg/m2/day for
3 days and cytarabine 100mg/m2/day for 7 days), received by
98.7% of patients during ﬁrst induction and 70% of patients
during re-induction. Overall CR rate was 80.1%, with 62.7%
and 15.6% of patients attaining CR after one and two cycles of
induction chemotherapy respectively. In addition, relapse
rates were similar in patients who achieved CR after one and
two cycles of induction chemotherapy (42.4% vs. 40.9%,
p¼0.94). Of note, among patients requiring re-induction,
there was no signiﬁcant difference in the CR rates between
the use of IA 3+7 and non-IA 3+7 regimen (p¼0.45). About
10% (n¼39) of patients had primary resistant AML, of which
seven of them achieved CR with salvage chemotherapy and
six relapsed later.
Multivariate analysis identiﬁed Malay race (OR: 18.6, 95%
CI 3.3 e 105.4) and patients with adverse risks (OR: 17.2, 95%
CI 3.1 e 97.3), deﬁned by the European Leukemia Net (ELN)
risk classiﬁcation, as predictors for primary resistant AML.
However, Malay race was not found to have a higher inci-
dence of adverse risks compared to non-Malay (p¼0.98).
Conclusion: Themost signiﬁcant ﬁnding from this studywas
that Malay race is associated with primary treatment resis-
tance to conventional induction chemotherapy. Further
studies may be warranted to identify other contributing
factors and optimize induction treatment for this subgroup
of patients.Figure 1. FIC50 of A) BU, B) MEL, C) FLU, D) C244
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Introduction: Busulfan (BU), melphalan (MEL), ﬂudarabine
(FLU), clofarabine (CLO), cytosine arabinoside (Ara-C), and
etoposide (VP-16) are widely used as conditioning re-
gimens for hematopoietic stem cell transplant (HSCT) for
myeloid and/or lymphoid malignancies. Among these
agents, BU has been used more often for patients with
myeloid malignancies. To show the priorities or inferiorities
of anti-tumor activities of both myeloid and lymphoid
leukemia cells in vitro, cytotoxicities of these 6 compounds
were compared between human myeloid and lymphoid
leukemia cell lines.
Materials and methods: The following human cell lines
were exposed to all 6 chemotherapeutic agents: promye-
locytic leukemia cell HL60; chronic myelogenous leukemia
cell K562; acute myelogenous leukemia cell KU-812; acute
monocytic leukemia cell THP-1; acute lymphoblastic leu-
kemia cells CCRF-CEM, MOLT-3, and MOLT-4; lympho-
blastoid cell WIL2-NS. Each cell line was exposed to each
agent for 72 hours at 4 digits varied concentrations in 96
well micro plate with triplicate wells containing 5,000 cells
in each well. Cell viabilities were determined by adding
WST-8 (Kishida Chemical Co., Ltd.) to each well and
reading absorbance of 450 nm wave length using multi
micro plate reader GloMax-Multi+ Detection System
(Promega KK).
The drug concentration capable of 50% growth inhibitory
concentration (IC50) was calculated using GraphPad Prism 6
(GraphPad Software, Inc.).
Results: The anti-tumor activities of these 6 chemothera-
peutic agents for both myeloid and lymphoid leukemia cell
lines were determined as IC50. K562 was resistant to all the
agents having the highest IC50 in all agents (high than 100,LO, E) Ara-C, and F) VP-16 for myeloid.
